Serum ferritin is a candidate biomarker of disease aggravation in amyotrophic lateral sclerosis

Yu,Jixu; Wang,Nian; Qi,Faying; Wang,Xianjun; Zhu,Qiyi; Lu,Yucheng; Zhang,Huiling; Che,Fengyuan; Li,Wei

doi:10.3892/br.2018.1138

Serum ferritin is a candidate biomarker of disease aggravation in amyotrophic lateral sclerosis

Authors:
- Jixu Yu
- Nian Wang
- Faying Qi
- Xianjun Wang
- Qiyi Zhu
- Yucheng Lu
- Huiling Zhang
- Fengyuan Che
- Wei Li
View Affiliations

Affiliations: Department of Neurology, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China, Central Laboratory, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China, Clinical Laboratory, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China
Published online on: August 2, 2018 https://doi.org/10.3892/br.2018.1138
Pages: 333-338

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. The mechanism that defines the loss of neurons in ALS is still not clearly understood, and there is no effective therapy to block its progression. Previous studies indicate that a disorder of iron homeostasis exists in ALS and based on this, the change of serum iron and ferritin and the association between iron metabolism and clinical features in Chinese Han patients with ALS was further investigated in the present study, in order to define its pathogenesis. Two cohorts were established: An ALS group consisting of 24 patients and a control group consisting of 38 healthy volunteers. Venous blood samples were collected for serum iron and ferritin analysis. The results indicated that the levels of serum iron were significantly decreased in patients with ALS (P<0.05), while there was no significant difference in serum ferritin between the ALS and control groups. However, the levels of serum ferritin were increased significantly in ALS patients with bulbar-onset (vs. limb-onset in females), dysphagia (vs. without dysphagia), longer disease duration (>12 months vs. ≤12 months in males) and lower ALS Functional Rating Scale-Revised score (<33 vs. ≥33; P<0.05). These results suggested that there was dysregulation of iron metabolism in Chinese Han patients with ALS and that serum ferritin may be a candidate biomarker of aggravation in these patients.

View Figures

View References

1	Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR and Zoing MC: Amyotrophic lateral sclerosis. Lancet. 377:942–955. 2011. View Article : Google Scholar : PubMed/NCBI
2	Hardiman O, van den Berg LH and Kiernan MC: Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 7:639–649. 2011. View Article : Google Scholar : PubMed/NCBI
3	Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul A, Benn E and Beghi E: EURALS: Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 81:385–390. 2010. View Article : Google Scholar : PubMed/NCBI
4	Couratier P, Corcia P, Lautrette G, Nicol M, Preux PM and Marin B: Epidemiology of amyotrophic lateral sclerosis: A review of literature. Rev Neurol (Paris). 172:37–45. 2016. View Article : Google Scholar : PubMed/NCBI
5	Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, McLaughlin R and Hardiman O: Rate of familial amyotrophic lateral sclerosis: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 82:623–627. 2011. View Article : Google Scholar : PubMed/NCBI
6	Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G and Chinea A: A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 6:1712015. View Article : Google Scholar : PubMed/NCBI
7	Holecek V and Rokyta R: Possible etiology and treatment of amyotrophic lateral sclerosis. Neuro Endocrinol Lett. 38:528–531. 2018.PubMed/NCBI
8	Redler RL and Dokholyan NV: The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci. 107:215–262. 2012. View Article : Google Scholar : PubMed/NCBI
9	Cookson MR and Shaw PJ: Oxidative stress and motor neurone disease. Brain Pathol. 9:165–186. 1999. View Article : Google Scholar : PubMed/NCBI
10	Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, et al: Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics. J Cell Physiol. 226:2484–2493. 2011. View Article : Google Scholar : PubMed/NCBI
11	Taylor JP, Hardy J and Fischbeck KH: Toxic proteins in neurodegenerative disease. Science. 296:1991–1995. 2002. View Article : Google Scholar : PubMed/NCBI
12	Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:59–62. 1993. View Article : Google Scholar : PubMed/NCBI
13	Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P and David S: Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 29:610–619. 2009. View Article : Google Scholar : PubMed/NCBI
14	Oshiro S, Morioka MS and Kikuchi M: Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci. 2011:3782782011.PubMed/NCBI
15	Hadzhieva M, Kirches E, Wilisch-Neumann A, Pachow D, Wallesch M, Schoenfeld P, Paege I, Vielhaber S, Petri S, Keilhoff G, et al: Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience. 230:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
16	Chen P, Miah MR and Aschner M: Metals and Neurodegeneration. F1000Res. Mar 17–2016.doi: 10.12688/f1000research.7431.1. View Article : Google Scholar
17	Veyrat-Durebex C, Corcia P, Mucha A, Benzimra S, Mallet C, Gendrot C, Moreau C, Devos D, Piver E, Pagès JC, et al: Iron metabolism disturbance in a French cohort of ALS patients. BioMed Res Int. 2014:4857232014. View Article : Google Scholar : PubMed/NCBI
18	Kasarskis EJ, Tandon L, Lovell MA and Ehmann WD: Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: A preliminary study. J Neurol Sci. 130:203–208. 1995. View Article : Google Scholar : PubMed/NCBI
19	Ince PG, Shaw PJ, Candy JM, Mantle D, Tandon L, Ehmann WD and Markesbery WR: Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci Lett. 182:87–90. 1994. View Article : Google Scholar : PubMed/NCBI
20	Hozumi I, Hasegawa T, Honda A, Ozawa K, Hayashi Y, Hashimoto K, Yamada M, Koumura A, Sakurai T, Kimura A, et al: Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci. 303:95–99. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zheng Y, Gao L, Wang D and Zang D: Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Acta Neurol Scand. 136:145–150. 2017. View Article : Google Scholar : PubMed/NCBI
22	Qureshi M, Brown RH Jr, Rogers JT and Cudkowicz ME: Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J. 2:51–54. 2008. View Article : Google Scholar : PubMed/NCBI
23	Goodall EF, Haque MS and Morrison KE: Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. J Neurol. 255:1652–1656. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ikeda K, Hirayama T, Takazawa T, Kawabe K and Iwasaki Y: Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: A cross-sectional study. Intern Med. 51:1501–1508. 2012. View Article : Google Scholar : PubMed/NCBI
25	Nadjar Y, Gordon P, Corcia P, Bensimon G, Pieroni L, Meininger V and Salachas F: Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis. PLoS One. 7:e450342012. View Article : Google Scholar : PubMed/NCBI
26	Su XW, Clardy SL, Stephens HE, Simmons Z and Connor JR: Serum ferritin is elevated in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 16:102–107. 2015. View Article : Google Scholar : PubMed/NCBI
27	Brooks BR: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop contributors. J Neurol Sci. 124:96–107. 1994. View Article : Google Scholar : PubMed/NCBI
28	Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R and Mohammadi B: ALSFRS-R score and its ratio: A useful predictor for ALS-progression. J Neurol Sci. 275:69–73. 2008. View Article : Google Scholar : PubMed/NCBI
29	Lechtzin N, Maragakis NJ, Kimball R, Busse A, Hoffman V and Clawson L: Accurate ALSFRS-R scores can be generated from retrospective review of clinic notes. Amyotroph Lateral Scler. 10:244–247. 2009. View Article : Google Scholar : PubMed/NCBI
30	Contestabile A: Amyotrophic lateral sclerosis: From research to therapeutic attempts and therapeutic perspectives. Curr Med Chem. 18:5655–5665. 2011. View Article : Google Scholar : PubMed/NCBI
31	Jomova K, Vondrakova D, Lawson M and Valko M: Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 345:91–104. 2010. View Article : Google Scholar : PubMed/NCBI
32	Boldt DH: New perspectives on iron: An introduction. Am J Med Sci. 318:207–212. 1999. View Article : Google Scholar : PubMed/NCBI
33	Qian ZM and Wang Q: Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Brain Res Rev. 27:257–267. 1998. View Article : Google Scholar : PubMed/NCBI
34	Rivera-Mancía S, Pérez-Neri I, Ríos C, Tristán-López L, Rivera-Espinosa L and Montes S: The transition metals copper and iron in neurodegenerative diseases. Chem Biol Interact. 186:184–199. 2010. View Article : Google Scholar : PubMed/NCBI
35	Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB and Perry G: Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis. 6:165–169. 2004. View Article : Google Scholar : PubMed/NCBI
36	Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA and Zhu X: Iron: The Redox-active center of oxidative stress in Alzheimer disease. Neurochem Res. 32:1640–1645. 2007. View Article : Google Scholar : PubMed/NCBI
37	Smith MA, Harris PL, Sayre LM and Perry G: Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA. 94:9866–9868. 1997. View Article : Google Scholar : PubMed/NCBI
38	Olsen MK, Roberds SL, Ellerbrock BR, Fleck TJ, McKinley DK and Gurney ME: Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol. 50:730–740. 2001. View Article : Google Scholar : PubMed/NCBI
39	Yu J, Guo Y, Sun M, Li B, Zhang Y and Li C: Iron is a potential key mediator of glutamate excitotoxicity in spinal cord motor neurons. Brain Res. 1257:102–107. 2009. View Article : Google Scholar : PubMed/NCBI
40	Langkammer C, Enzinger C, Quasthoff S, Grafenauer P, Soellinger M, Fazekas F and Ropele S: Mapping of iron deposition in conjunction with assessment of nerve fiber tract integrity in amyotrophic lateral sclerosis. J Magn Reson Imaging. 31:1339–1345. 2010. View Article : Google Scholar : PubMed/NCBI
41	Mitchell RM, Simmons Z, Beard JL, Stephens HE and Connor JR: Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve. 42:95–103. 2010. View Article : Google Scholar : PubMed/NCBI
42	Petri S, Körner S and Kiaei M: Nrf2/ARE signaling pathway: Key mediator in oxidative stress and potential therapeutic target in ALS. Neurol Res Int. 2012:8780302012. View Article : Google Scholar : PubMed/NCBI
43	Wang Q, Zhang X, Chen S, Zhang X, Zhang S, Youdium M and Le W: Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis. 8:310–321. 2011. View Article : Google Scholar : PubMed/NCBI
44	Golko-Perez S, Mandel S, Amit T, Kupershmidt L, Youdim MB and Weinreb O: Additive Neuroprotective effects of the multifunctional iron chelator M30 with enriched diet in a mouse model of amyotrophic lateral sclerosis. Neurotox Res. 29:208–217. 2016. View Article : Google Scholar : PubMed/NCBI
45	Greenwood DI: Nutrition management of amyotrophic lateral sclerosis. Nutr Clin Pract. 28:392–399. 2013. View Article : Google Scholar : PubMed/NCBI
46	Traynor BJ, Codd MB, Corr B, Forde C, Frost E and Hardiman OM: Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol. 57:1171–1176. 2000. View Article : Google Scholar : PubMed/NCBI
47	Molfino A, Kushta I, Tommasi V, Fanelli Rossi F and Muscaritoli M: Amyotrophic lateral sclerosis, enteral nutrition and the risk of iron overload. J Neurol. 256:1015–1016. 2009. View Article : Google Scholar : PubMed/NCBI
48	Yu J, Qi F, Wang N, Gao P, Dai S, Lu Y, Su Q, Du Y and Che F: Increased iron level in motor cortex of amyotrophic lateral sclerosis patients: An in vivo MR study. Amyotroph Lateral Scler Frontotemporal Degener. 15:357–361. 2014. View Article : Google Scholar : PubMed/NCBI